Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Rituximab in Treatment Naïve Follicular Lymphoma (PERSPECTIVE)
NCT02947347Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Jan 2017
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing (Arm A) ibrutinib + rituximab with (Arm B) placebo + rituximab (2 arms). Primary endpoint: Progression-Free Survival at 53.75 months. Started Jan 2017; status: completed.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02947347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947347.